維亞生物(01873.HK)擬參投行業基金 聚焦醫藥早期創新項目
格隆匯5月28日丨維亞生物(01873.HK)發佈公告,2025年5月28日,杭州維亞宗晨(公司全資附屬公司)、南京瑞弘、南京高質量、南京生物醫藥谷、南京揚子、南京北聯、南京新城、南京高新、上海鑫欣、博瑞生物醫藥及江蘇鼎泰訂立合夥協議,據此,訂約方同意成立該基金,杭州維亞宗晨將作爲有限合夥人蔘與新成立的該基金。根據合夥協議,杭州維亞宗晨同意於該基金投資人民幣2500萬元。
該基金(暫定名稱爲南京弘暉維泰創業投資基金合夥企業(有限合夥))將主要聚焦醫藥行業內的早期開發項目,重點關注生命科學領域的前沿技術創新及轉化。參與及投資該基金將加強集團對醫藥行業最新動態的瞭解,有助集團尋求潛在戰略夥伴及與其業務的協同效應,尤其是專注於服務早期醫藥方案的合同研究組織業務。此外,有關投資將令公司積累與潛在投資者及醫藥初創公司未來合作的經驗,拓闊集團的行業網絡,爲集團的服務換股權(EFS)孵化模式探索可能的備選模式。
公司認爲,南京瑞弘(透過王暉先生及其對行業的個人瞭解以及其他利益相關人士)將令該基金獲益,有鑑於此及合夥人的經驗及網絡,公司認爲,集團參與該基金可令其有效利用現有財務資源,提高潛在資本收益。集團將作出的出資不會對集團的財務狀況及經營業績產生任何不利影響。集團擬使用內部資源撥付對該基金的出資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.